Trial Profile

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBC Ab002 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; First in man
Sponsors ImmunoBrain Checkpoint

Most Recent Events

14 Jul 2026 Results presented in the ImmunoBrain Checkpoint media release
14 Jul 2026 According to an ImmunoBrain Checkpoint media release, data from phase Ib trial presented at the Alzheimer's Association International Conference (AAIC) 2026.
14 Jul 2026 According to an ImmunoBrain Checkpoint media release, data from phase Ib trial published in Nature Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com